Association between mean platelet volume levels and inflammation in SLE patients presented with arthritis

Background: Systemic lupus erythematosus (SLE) may be characterized by periods of remissions and chronic or acute relapses. The complexity of clinical presentation of the SLE patients leads to incorrect evaluation of disease activity. Mean platelet volume (MPV) has been studied as a simple inflammatory marker in several diseases. There is no study in the literature about MPV levels in adult SLE patients with arthritis.Objectives: We aimed to investigate the MPV levels in the SLE population with arthritis during and between activations.Methods: The study consisted of 44 SLE patients with arthritis in activation period (Group 1), the same 44 SLE patients with arthritis in remission period (Group 2) and 44 healthy controls (Group 3). Erythrocyte sedimentation rate (ESR), creactive protein (CRP), white blood cell count, platelet count, and mean platelet volume (MPV) levels were retrospectively recorded from patient files.Results: The mean ages of the SLE subjects were 42 ± 16 years, while the mean ages of controls was 41 ± 17 years. MPV was significantly lower in Group 1(7.66±0.89fL) than in Group 2 (8.61±1.06 fL) and Group 3(8.62±1.11fL) (p<0.0001). The differences between groups reached statistical significance.Conclusions: We suggest that MPV levels decrease in patients with arthritis of SLE activation when compared to the same patients in remission and healthy controls.Key words: Systemic lupus erythematosus, Arthritis, Mean platelet volum

Relationship between prevalence and severity of restless legs syndrome and anemia in patients with systemic lupus erythematosus

PMID = 2662178

Arsenic trioxide-loaded, microemulsion-enhanced cytotoxicity on MDAH 2774 ovarian carcinoma cell line

WOS: 000236943200011PubMed ID: 16681722The antiproliferative effect of As2O3-loaded microemulsion (As2O3-M) on human MDAH 2774 ovarian cancer cells was compared with a regular solution of the As2O3. We used MDAH 2774 as model cell lines for ovarian cancer. The (2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)carbonyl]-2H-tetrazolium hydroxide) (XTT) and trypane blue dye exclusion tests were used to evaluate cytotoxicity. Apoptotic effect of solutions was evaluated using cell death detection kit. Standard microemulsion formulation used in this experiment contains 5 x 10(-6) M As2O3. It was clearly demonstrated that As2O3-M had a significant cytotoxic effect on MDAH 2774 cell line, and the cytotoxic effect of As2O3-M was significantly higher than that of regular As2O3 solutions. Even approximately 6000 times diluted microemulsion formulation loaded with 5 x 10(-6) M As2O3 showed a cytotoxic effect. As a result, this diluted concentration (approximately 8 x 10(-10) M) was found to be approximately 6000 times more effective than regular As2O3 solutions (5 x 10(-6) M). Moreover, this diluted concentration resulted in 1.5-fold enhancement of apoptosis. According to the in vitro cytotoxicity studies, we concluded that by incorporating As2O3 into the microemulsion (As2O3-M), which is a new drug carrier system, it is possible to increase antiproliferative effect of regular As2O3 on MDAH 2774 cells. Translating these results to in vivo conditions would open new windows in the treatment of ovarian cancer

AN ASSESSMENT OF SLEEP DISTURBANCES AND QUALITY OF LIFE IN PRIMARY

Introduction: It was aimed to evaluate sleep disturbances and quality of life in primary Sjogren's syndrome (pSS) patients and to evaluate any relationship with urinary incontinence.Methods: The study included 77 voluntary patients admitted to the rheumatology clinic. The control group consisted of 80 healthy individuals. All participants were requested to complete the Pittsburgh Sleep Quality Index (PSQI), Epworth Sleepines Scale (ESS), International Restless Leg Syndrome (RLS) study group (IRLSSG) rating scale, and SF-36 quality of life questionnaire. The age of pSS onset, age at diagnosis, and age at the beginning of therapy were recorded. Patients with urinary incontinence were evaluated with the incontinence severity index(ISI).Results: The mean scores of the mental health, general health, vitality, physical function, physical role function and emotional role function parameters of the patients were statistically significantly lower than those of healthy volunteers. In the ESS scale, the average score was found to be 7.9 +/- 2.8 in the patient group and 4.5 +/- 2.1 in the control group. The average IRLSSG rating scale score was 13.4 +/- 7.6 in the patient group and 5.4 +/- 5.2 in the control group. The total PSQI score was 7.8 +/- 3.5 in the patient group and 4.11 +/- 1.64 in the control group. There was a statistically significant difference in terms of ESS, IRLSSG rating scale and sleep quality scores. Patients with urinary incontinence (n=26) had significantly higher PSQI and SF-36 scores than patients without urinary incontinence (n=51).Conclusion: Patients diagnosed with pSS have a significantly decreased sleep quality and HRQOL compared with the normal population. Urinary incontinence had a negative impact on sleep and HRQOL. RLS, sleepiness and urinary incontinence are common in patients with pSS